Edwards Lifesciences (EW) Long-Term Investments (2009 - 2026)

Edwards Lifesciences has reported Long-Term Investments for 18 years, with the latest figure at $285.6 million in Q1 2026.

• For the quarter ending Q1 2026, Long-Term Investments rose 2.77% year-over-year to $285.6 million; the trailing twelve-month figure through Mar 2026 stood at $285.6 million (up 2.77% YoY), and the FY2025 full-year result was $278.6 million, down 9.52% from the prior year.
• Long-Term Investments for Q1 2026 stood at $285.6 million, up from $278.6 million in the prior quarter.
• The five-year high for Long-Term Investments was $1.6 billion in Q1 2022, with the low at $274.7 million in Q3 2025.
• Average Long-Term Investments over 5 years is $694.0 million, with a median of $455.6 million recorded in 2024.
• Year-over-year, Long-Term Investments soared 102.41% in 2022 and plunged 58.74% in 2024.
• Tracing EW's Long-Term Investments over 5 years: stood at $1.2 billion in 2022, then tumbled by 52.87% to $583.9 million in 2023, then plunged by 47.27% to $307.9 million in 2024, then decreased by 9.52% to $278.6 million in 2025, then grew by 2.51% to $285.6 million in 2026.
• The last three Long-Term Investments figures came in at $285.6 million (Q1 2026), $278.6 million (Q4 2025), and $274.7 million (Q3 2025), per Business Quant data.

Peer Comparison